Many large pharmaceutical companies are increasingly turning to acquisitions rather than relying solely on internal research and development efforts to build their drug pipelines. That shift is shaping what legal departments need from their lawyers, said Beth Long, managing partner of the Philadelphia office of Major, Lindsey & Africa.
Many large pharmaceutical companies are increasingly turning to acquisitions rather than relying solely on internal research and development efforts to build their drug pipelines. That shift is shaping what legal departments need from their lawyers, said Beth Long, managing partner of the Philadelphia office of Major, Lindsey & Africa.
